Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imipramine in untreated triple negative breast cancer
NCT03122444Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Jul 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imipramine in triple-negative breast cancer (TNBC), sponsored by UT Health San Antonio. Primary endpoint: Proliferation rate of triple negative breast cancer at 30 days. Started Jul 2019; status: completed.
02
Drugs
imipramine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03122444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03122444.